| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | |||||||||
Net loss | |||||||||
-8,599 | -8,583 | -7,023 | -6,750 | -5,467 | -4,519 | -3,266 | -2,582 | -2,363 | -2,081 |
Adjustments to reconcile net loss to net cash used in operating activities | |||||||||
Technology impairment | |||||||||
- | - | - | - | - | - | - | 345 | 345 | - |
Common stock issed for services | |||||||||
- | - | - | - | - | - | - | 18 | 0 | - |
Stock-based compensation | |||||||||
684 | 554 | 793 | 784 | 369 | 404 | 704 | 63 | 382 | 477 |
Amortization of technology license | |||||||||
0 | 161 | - | - | - | - | - | - | - | - |
Amortization of right of use assets | |||||||||
96 | 0 | - | - | - | - | - | - | - | - |
Amortization | |||||||||
- | - | 160 | 161 | 161 | 161 | 160 | 185 | 211 | 197 |
Depreciation | |||||||||
134 | 265 | 251 | 43 | 41 | 10 | 0 | 0 | - | - |
Impairment of technology license | |||||||||
0 | 608 | 0 | - | - | - | - | - | - | - |
Change in fair value of warrant liability | |||||||||
- | - | -2,374 | -1,713 | 0 | 0 | - | - | - | - |
Loss on extinguishment of warrant liability | |||||||||
- | - | -440 | 0 | - | - | - | - | - | - |
(Increase) decrease in operating assets | |||||||||
Prepaid drug product for testing | |||||||||
444 | -785 | 741 | -184 | 405 | 104 | - | - | - | - |
Grants receivable | |||||||||
- | - | - | - | - | - | - | - | 244 | 244 |
Prepaid drug product for testing | |||||||||
- | - | - | - | - | - | -143 | 42 | -64 | -520 |
Other current assets | |||||||||
-15 | 450 | -549 | 723 | 79 | 36 | 21 | -5 | 24 | -1 |
Increase (decrease) in operating liabilities | |||||||||
Accounts payable and accrued expenses | |||||||||
-168 | 536 | -12 | -146 | 375 | 267 | -34 | 13 | 69 | -18 |
Lease liabilities | |||||||||
79 | 0 | - | - | - | - | - | - | - | - |
Deferred revenue | |||||||||
- | - | - | 12 | 0 | 0 | - | - | - | - |
Net cash used in operating activities | |||||||||
- | - | - | - | -5,005 | -3,817 | -2,313 | -1,993 | - | - |
Net cash used in operating activities | |||||||||
-8,361 | -6,124 | -7,957 | -8,148 | - | - | - | - | -1,149 | -1,148 |
Cash flow from investing activities | |||||||||
Purchase of exclusive license - related party | |||||||||
- | - | - | - | - | - | - | 25 | 170 | 229 |
Purchases of furniture, fixtures & equipment | |||||||||
0 | 17 | 538 | 338 | 0 | 123 | 0 | 0 | - | - |
Net cash used in investing activities | |||||||||
0 | -17 | -538 | -338 | - | - | - | - | -170 | -229 |
Cash flow from financing activities | |||||||||
Proceeds from convertible notes | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Cash repayment of convertible notes | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Net proceeds from sale of common stock | |||||||||
26,700 | 1,180 | 3,567 | 9,007 | - | - | 5,330 | 1,600 | 2,033 | 1,049 |
Net proceeds from sale of common stock and warrants | |||||||||
- | - | - | - | 0 | 13,812 | - | - | - | - |
Net proceeds from exercise of warrants | |||||||||
1,083 | 0 | 1,518 | 0 | 0 | 435 | 0 | 0 | - | - |
Net cash used in investing activities | |||||||||
- | - | - | - | 0 | -123 | 0 | -25 | - | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 0 | 14,247 | 5,330 | 1,600 | - | - |
Net cash provided by financing activities | |||||||||
27,783 | 1,180 | 5,085 | 9,007 | - | - | - | - | 2,033 | 1,049 |
Net increase (decrease) in cash | |||||||||
19,422 | -4,961 | - | - | - | - | - | - | - | - |
Supplemental disclosure of non-cash activities | |||||||||
Non-cash investing activities | |||||||||
Addition to leasehold improvements | |||||||||
31 | 0 | - | - | - | - | - | - | - | - |
Net increase (decrease) in cash | |||||||||
- | - | -3,410 | 521 | -5,005 | 10,307 | 3,017 | -418 | 713 | -328 |
Interest | |||||||||
- | - | - | - | - | - | 0 | 0 | 0 | 0 |
Income taxes | |||||||||
- | - | - | - | - | - | 0 | 0 | 0 | 0 |
Warrants transferred to equity upon modification | |||||||||
- | - | 797 | 0 | - | - | - | - | - | - |
Conversion of warrant liability to equity | |||||||||
- | - | 175 | 0 | - | - | - | - | - | - |
Capital expenditures included in accrued expenses | |||||||||
- | - | - | 247 | 0 | 0 | - | - | - | - |
Common stock issued upon conversion of convertible notes | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Common stock issued to Placement Agent | |||||||||
- | - | - | - | - | - | 771 | 0 | - | - |
Due diligence and commitment shares issued | |||||||||
- | - | - | - | - | - | - | 1 | - | - |